Think Ottawa Medicine

bloodclot

Division of Hematology

Noteworthy Publications

Division member published over 80 peer reviewed publications in 2010–2011 with notable publications in high impact journals including:

EINSTEIN Investigators, Bauersachs, R, Berkowitz, SD, Brenner, B, Buller, HR, Decousus, H, Gallus, AS, Lensing, AW, Misselwitz, F, Prins, MH, Raskob, GE, Segers, A, Verhamme, P, Wells, P, Agnelli, G, Bounameaux, H, Cohen, A, Davidson, BL, Piovella, F, Schellong, S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26):2499-2510

Carrier, M, Le Gal, G, Wells, P, Rodger, M. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010;152(9):578-89

Bourjeily, G, Paidas, M, Khalil, H, Rosene-Montella, K, Rodger, M (senior author). Pulmonary embolism in pregnancy. Lancet 2010; 375(9713):500-12

Rodger, MA, Betancourt, MT, Clark, P, Lindqvist, PG, Dizon-Townson, D, Said, J, Seligsohn, U, Carrier, M, Salomon, O, Greer, IA. The association of factor V leiden and prothrombin gene mutation and placenta mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 15:7(6)

Sabloff, M, Chandy, M, Wang, Z, Logan, BR, Ghavamzadeh, A, Li, CK, Irfan, SM, Bredeson, CN, Cowan, MJ, Gale, RP, Hale, GA, Horan, J, Hongeng, S, Eapen, M, Walters, MC. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood 2011; 117(5):1745-50

Kekre, N, Chou, A, Tokessey, M, Doucette, S, Tinmouth, A, Tay J, Allan, DS.Storage time of transfused red blood cells and impact on clinical outcomesin hematopoietic stem cell transplantation. Transfusion 2011;51(11):2488-94

McDiarmid, S, Hutton, B, Atkins, H, Bence-Bruckler, I, Bredeson, C, Sabri, E, Huebsch, L. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010;45(7):1220-6

 

Key Grants

Atkins, H. Multiple Sclerosis Society of Canada. Autologous Mesenchymal Stem Cell Transplantation: A potential cell-based treatment for inflammatory forms of Multiple Sclerosis

Carrier, M. Heart and Stroke Foundation of Canada. Screening for previously undiagnosed malignancy in patients with unprovoked Venous thromboembolism: a randomized controlled trial using a comprehensive computed tomography of the abdomen/pelvis

Carrier, M. CIHR. The Use of Extended Peri-operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Randomized Controlled Trial

Rodger, M. CIHR and NIH. A Pilot Study Assessing Feasibility of a Randomized, Placebo-controlled Trial of Low Molecular Weight Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism

Tay, J. Canadian Blood Services. Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation

Tinmouth, A. Canadian Blood Services. University of Ottawa Centre for Transfusion Research: Infrastructure Support for Transfusion Research

 

 Overview

The Division of Hematology has three pillars of strength: Thrombosis, Transfusion Medicine and Malignant Hematology. These pillars are focused on:

  1. Provision of high quality and safe cost effective patient care,
  2. Developing tommorow’s leader and
  3. Practice Changing Research

This past spring, the Division consolidated under a single roof in “The Ottawa Blood Disease Center of Excellence” strategically located in a new Practice Changing Research building (between Roger Guindon Hall and The Ottawa Hospital General Campus). Our Division and its members are very excited by the synergies and collegiality that this proximity will generate.

The Division’s members deliver:

  1. Tertiary and Quaternary Blood Care in over 30,000 outpatient visits per year and over 2000 inpatient stays including >100 bone marrow transplants per year,
  2. Blood Education from the medical student level to developing tomorrow’s leaders in sub-specialty hematology including our world leading Thrombosis fellowship and Transfusion fellowship and
  3. Practice Changing Blood Research in Thrombosis and Transfusion, 2 of The Ottawa Hospital’s academic priorities, with over 10 million in peer reviewed funding from >8 clinician scientists delivering a New England Journal of Medicine publication q2 yearly.

Research

Our research programs have led to important changes in clinical practice. These achievements are a result of team work. The team consists of 18 Hematologists, 2-4 Thrombosis Fellows, 2-4 BMT fellows, 4-8 Hematology residents, >25 clinical research personnel, 16 assistants and 10 clinical allied health professionals.

Education

The Hematology Residency Training Program is proud to provide an extremely strong training experience that is fully accredited by the Royal College of Physicians and Surgeons of Canada. The residents that complete our program have a sound knowledge base and become competent and self reliant hematologists after a two year training program whose focus is optimizing learning experiences.  Our program benefits from having a strong Bone Marrow Transplant Program (in particular, a second-to-none inter-disciplinary team providing innovative, high quality, ethical and empathic care) as well as an internationally renowned Thrombosis Program (with world-class research funding and productivity).  Few programs in the country can boast strengths in both these content areas of clinical hematology (malignant hematology and thrombosis) and these two important aspects of academic life (patient care and research).

The division of Hematology offers many diverse elective opportunities for internal and visiting clerkship students and residents.

Patient Care

The Thrombosis Program delivers outpatient management of DVT/PE and anticoagulant therapy through over 15,000 clinic visits per year. This program has led innovations which have permitted the transition of care of these patients from an inpatient to an outpatient setting through more safe and cost-effective diagnostic and treatment strategies.

The Ottawa Hospital BMT program, the first program accredited in Canada, celebrated its 10th year of Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) accreditation. Furthermore, after the most recent accreditation visit/report, we learned that the accreditation score was the highest ever recorded for any program in North America FACHT accreditation, highlighting the clinical excellence of our BMT group.

 The Ottawa Hospital BMT program, in addition to be being one of only a handful of centers to treat multiple sclerosis with autologous stem cell transplants has expanded this innovative approach to other life threatening autoimmune diseases for patients from across Canada.

Notable Honours and Achievements in 2010-2011:

Dr. Marc Carrier – received a University of Ottawa, Faculty of Medicine Tier 2 Research Chair in “Cancer and Venous Thrombosis”

Dr. Marc Rodger  - received a University of Ottawa, Faculty of Medicine Tier 1 Research Chair in “Venous Thrombosis and Thrombophilia”

Dr. Mitchell Sabloff  - recipient of a 2010 COMPASS award for compassionate care and exemplary multi-disciplinary teamwork

Dr. Melissa Forgie - received 2 Faculty of Medicine Excellence Awards for 1) Compétence être humain and 2) Compétence avocat-défenseur de la santé

Dr. Melissa Forgie- named Associate Dean of Undergraduate Medicine

Dr. David Allan - CIHR New Investigator Award for his bench research work on vascular stem cells.

Location

THE OTTAWA HOSPITAL, CIVIC CAMPUS, 1053 Carling Avenue, Ottawa ON  K1Y 4E9

THE OTTAWA HOSPITAL, GENERAL CAMPUS, 501 Smyth Road, Ottawa ON  K1H 8L6

© Copyright 2010 Department of Medicine in Ottawa